(Q30433197)

21 June 2017

Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer (English)

1 reference

non-small-cell lung carcinoma

21 June 2017

1 reference

5

David R Jones

1 reference

21 June 2017

Chadrick E Denlinger

1

1 reference

21 June 2017

Michael D Keller

series ordinal

2

1 reference

21 June 2017

Marty W Mayo

series ordinal

3

1 reference

21 June 2017

R Michael Broad

series ordinal

4

1 reference

21 June 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

The Journal of Thoracic and Cardiovascular Surgery

21 June 2017

1 reference

21 June 2017

127

1 reference

21 June 2017

1078-1086

1 reference

21 June 2017

4

1 reference

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Lung cancer--time to move on from chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Histone deacetylase inhibitors in cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Histone deacetylase inhibitors as new cancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Role of the histone deacetylase complex in acute promyelocytic leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Role of histone deacetylases in acute leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Inhibition of nuclear factor kappaB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Development of the proteasome inhibitor PS-341.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2803%2901321-7

10.1016/S0022-5223(03)01321-7

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference